AGP Executive Report
Last update: 7 hours agoObesity Drug Safety: Sweden’s Medical Products Agency warns against “click method” dose-stretching of tirzepatide/semaglutide, stressing pens may be unstable outside approved use and incorrect dosing can raise risks. Diabetes Tech Reality Check: A Swedish review in JAMA Internal Medicine finds no health benefit of continuous glucose monitors for people without diabetes and says built-in measurement error can mislead healthy users. Heart Failure Progress (Sweden): Swedish registry data show 1-year mortality for advanced heart failure fell from 2003 to 2022, mainly via lower cardiovascular deaths, but uptake of advanced therapies remains low. Infection Resistance: A global analysis reports over one-third of invasive E. coli isolates are multidrug-resistant, with Sweden among the lowest-rate countries. Dementia Prevention (Sweden-linked): Research using Swedish cohorts suggests mentally engaging sedentary habits (like reading) may lower dementia risk versus mentally passive ones (like TV). Cancer Research: Fixed-duration cevostamab shows promising response rates in relapsed/refractory multiple myeloma, supporting FcRH5 as a key target. Wellness & Care: Sweden strengthens Ukraine’s health and medical frontline via partnership funding, while a Swedish authority highlights the need for safe, evidence-based dosing and monitoring.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
